Preferred Label : acrylamides;
MeSH definition : Colorless, odorless crystals that are used extensively in research laboratories for
the preparation of polyacrylamide gels for electrophoresis and in organic synthesis,
and polymerization. Some of its polymers are used in sewage and wastewater treatment,
permanent press fabrics, and as soil conditioning agents.;
MeSH annotation : ACRYLAMIDE is also available;
Codes EINECS : 201-173-7;
Is substance : O;
Origin ID : D000178;
UMLS CUI : C0001218;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Indexing information
MeSH Descriptor(s) used for indexing
Record concept(s)
Related MeSH Supplementary Concept(s)
- AL 3264 [MeSH Supplementary Concept]
- ASP9853 [MeSH Supplementary Concept]
- BLU9931 [MeSH Supplementary Concept]
- IS 001 [MeSH Supplementary Concept]
- KPT-276 [MeSH Supplementary Concept]
- LQM330 [MeSH Supplementary Concept]
- LQM336 [MeSH Supplementary Concept]
- NED-180 [MeSH Supplementary Concept]
- PLS-123 [MeSH Supplementary Concept]
- POHABA [MeSH Supplementary Concept]
- RGFP966 [MeSH Supplementary Concept]
- WP-1034 [MeSH Supplementary Concept]
- WZ4002 [MeSH Supplementary Concept]
- heclin [MeSH Supplementary Concept]
- polgel [MeSH Supplementary Concept]
Semantic type(s)
Validated automatic mappings to BTNT
Colorless, odorless crystals that are used extensively in research laboratories for
the preparation of polyacrylamide gels for electrophoresis and in organic synthesis,
and polymerization. Some of its polymers are used in sewage and wastewater treatment,
permanent press fabrics, and as soil conditioning agents.
2024
false
false
false
France
French
osimertinib
summary of product characteristics
package leaflet
guidelines for drug use
administration, oral
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
bronchial neoplasms
bronchial neoplasms
EGF Receptors
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
osimertinib
EGFR NP_005219.2:p.L858R
EGFR Exon 19 Deletion Mutation
ErbB Receptors
acrylamides
aniline compounds
---
https://www.has-sante.fr/jcms/p_3168614/fr/tagrisso
2020
false
false
false
France
administration, oral
adult
insurance, health, reimbursement
antineoplastic agents
protein kinase inhibitors
neoplasm metastasis
carcinoma, non-small-cell lung
bronchial neoplasms
Activating EGFR Gene Mutation
osimertinib
osimertinib
evaluation of the transparency committee
piperazines
acrylamides
aniline compounds
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1265
2019
false
false
false
false
France
comparative effectiveness research
treatment outcome
EGFR Gene Mutation
protein kinase inhibitors
protein-tyrosine kinases
antineoplastic agents
Gefitinib
Afatinib
clinical trials, phase iii as topic
antineoplastic agents
protein kinase inhibitors
lung neoplasms
lung neoplasms
carcinoma, non-small-cell lung
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
critical appraisal or critical reading
carcinoma, non-small-cell lung
piperazines
piperazines
acrylamides
aniline compounds
acrylamides
aniline compounds
---
https://centres-antipoison.net/palytoxine-2
2018
false
false
false
false
France
French
technical report
seawater
reticulum
Stress fracture
poison control centers
corals
Water
salt water
due to
palytoxin
effects of exposure to external cause, nos
report
central
Folliculitis
data collection
Exhibition
albumin/globulin ratio
case study
persons
Water
anthozoa
research report
Exhibition
case reports
acrylamides
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1204
2018
false
false
false
Canada
French
osimertinib
due to
Pemetrexed
mutation
Chemotherapy
"u" lymphocyte
platinum
receptors, opioid, mu
platinum, nos
neoplasm, malignant
Cell
carcinoma, non-small-cell lung
small cell lung carcinoma
drug therapy
base, nos
chemotherapy, nos
treaties
Lung cancer
chemotherapy
small cell lung carcinoma
international cooperation
piperazines
ErbB Receptors
acrylamides
aniline compounds
acrylamides
aniline compounds
---
https://www.has-sante.fr/portail/jcms/c_2794988/fr/tagrisso-osimertinib-inhibiteur-de-tyrosine-kinase
https://www.has-sante.fr/portail/jcms/c_2794988/fr/tagrisso
2017
false
false
false
false
France
French
treatment outcome
piperazines
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
osimertinib
guidelines for drug use
EGFR NP_005219.2:p.T790M
comparative effectiveness research
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
---
https://www.ema.europa.eu/medicines/human/EPAR/Tagrisso
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
piperazines
piperazines
pregnancy
breast feeding
drug interactions
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
antineoplastic agents
carcinoma, non-small-cell lung
genetic testing
administration, oral
protein kinase inhibitors
protein kinase inhibitors
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
product surveillance, postmarketing
drug monitoring
contraception
drug evaluation, preclinical
osimertinib
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
acrylamides
aniline compounds
---
http://www.has-sante.fr/portail/jcms/c_2676714/fr/tagrisso
http://www.has-sante.fr/portail/jcms/c_2676714/fr/tagrisso-osimertinib-inhibiteur-de-tyrosine-kinase
2016
false
false
false
France
French
treatment outcome
piperazines
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
osimertinib
guidelines for drug use
EGFR NP_005219.2:p.T790M
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
---
https://ansm.sante.fr/tableau-atu-rtu/azd9291-40-et-80-mg-comprime-pellicule
2015
false
false
false
France
French
adult
pharmacovigilance
continuity of patient care
acrylamides
acrylamides
aniline compounds
aniline compounds
administration, oral
carcinoma, non-small-cell lung
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Stage IV Lung Non-Small Cell Cancer AJCC v7
neoplasm metastasis
EGFR Gene Mutation
osimertinib
drug information
AZD9291
ErbB Receptors
---